Fundraising Fox
Nok Therapeutics
OTC: NKTPCranberry Twp., US · Founded 2024 · Florida corporation
Find your way into Nok Therapeutics
Sign up to see every warm intro you have to Nok Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nok Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NOK Therapeutics is a biotech company developing autologous Natural Killer (NK) cell therapies for cancer treatment that avoid the need for lymphodepletion. The company is an early-stage oncology/immunotherapy business raising capital through a Regulation A+ pre-IPO offering.
Founders & leadership
BC
Brian CogleyExecutive
RL
Robert LewisNo family relationship with Martin Lewis or Michael Lewis
ML
Martin LewisNo family relationship with Michael Lewis or Robert Lewis
Board
BC
Bruce CassidyBoard director
Reported raises · per SEC filings
Form D private placements$1.4M disclosed across 3 rounds · 2024
▶$750.5KraisedMay 2026 · 5 investors · BiotechnologyRule 506(b)
▶$750.5KraisedMay 2026 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LewisExecutive Officer, Director, Promoter
- David MehalickPromoter
- Michael LewisPromoter
- Bruce CassidyDirector
- Brian CogleyExecutive Officer, Director
- Martin LewisDirector
- Amount sold
- $750.5K
- Proceeds to insiders
- $315K
- First sale
- Oct 2024
- Incorporated
- Corporation, Florida, 2024
- Federal exemptions
- 06b
▶$3.2KraisedMay 2026 · 14 investors · BiotechnologyRule 506(b)
▶$3.2KraisedMay 2026 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian CogleyExecutive Officer, Director
- David MehalickPromoter
- Michael LewisPromoter
- Bruce CassidyDirector
- Robert LewisExecutive Officer, Director, Promoter
- Martin LewisDirector
- Offering amount
- $3.2K
- Amount sold
- $3.2K
- Minimum investment
- $100
- First sale
- Jun 2024
- Incorporated
- Corporation, Florida, 2024
- Federal exemptions
- 06b
▶$649KraisedApr 2026 · 17 investors · BiotechnologyRule 506(b)
▶$649KraisedApr 2026 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert LewisExecutive Officer, Director, Promoter
- Martin LewisDirector
- David MehalickPromoter
- Bruce CassidyDirector
- Michael LewisPromoter
- Brian CogleyExecutive Officer, Director
- Offering amount
- $750K
- Amount sold
- $649K
- Minimum investment
- $500
- Proceeds to insiders
- $315K
- First sale
- Aug 2024
- Incorporated
- Corporation, Florida, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
NKore BiotherapeuticsNKore BioTherapeutics is a cellular-based biotherapeutics company developing an allogeneic immunotherapy platform based on a proprietary method of activating natural killer (NK) cells, called Supercharged NK (sNK) cells. Its lead therapy, NK101, targets solid and blood cancers in adult and pediatric patients, with human clinical trials planned in the United States beginning in 2027.
NKILT TherapeuticsNKILT Therapeutics is a cell therapy biotech developing engineered immune cells, starting with natural killer (NK) cells, to target leukemias and solid tumors. It uses a proprietary Chimeric ILT-Receptor (CIR) binding technology to create off-the-shelf, allogeneic cancer treatments targeting the HLA-G immune checkpoint molecule.
NK-One TherapeuticsNK-One Therapeutics is a biotechnology company developing a first-in-class intrathecal molecular therapy (SP-SAP) that selectively disables NK-1 receptor pain-signaling neurons in the spine to treat refractory pain in end-stage cancer patients. The therapy is in a Phase 1 clinical trial and is also intended for veterinary use.
Nkarta, Inc.Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
CelularityCelularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.
Companies working in the same space as Nok Therapeutics.
Frequently asked questions
- What does Nok Therapeutics do?
- NOK Therapeutics is a biotech company developing autologous Natural Killer (NK) cell therapies for cancer treatment that avoid the need for lymphodepletion. The company is an early-stage oncology/immunotherapy business raising capital through a Regulation A+ pre-IPO offering.
- How much funding has Nok Therapeutics raised?
- Nok Therapeutics has disclosed $1.4M raised across 3 rounds.
- Where is Nok Therapeutics headquartered?
- Nok Therapeutics is headquartered in Cranberry Twp., US.